Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 4:57 PM ET

Pharmaceuticals

Company Overview of Novartis Vaccines and Diagnostics, Inc.

Company Overview

Novartis Vaccines and Diagnostics, Inc. manufactures vaccines. The company offers pharmaceuticals products in the therapeutic areas of hypertension, metabolism, infectious diseases, neuroscience, oncology, ophthalmology, respiratory, rheumatology and auto immunity, transplantation, and others. It also offers ophthalmic surgical portfolio that includes technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts, including refractive errors, such as presbyopia and astigmatism; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; treatment options f...

350 Massachusetts Avenue

Cambridge, MA 02139

United States

Founded in 2006

Phone:

617-871-7000

Fax:

617-871-8911

Key Executives for Novartis Vaccines and Diagnostics, Inc.

Chief Executive Officer
Age: 55
Deputy Chief Financial Officer
Age: 56
Head of Region North America and President of US Vaccines
Division Head
Age: 43
Head of Group Country Management & External Affairs
Compensation as of Fiscal Year 2015.

Novartis Vaccines and Diagnostics, Inc. Key Developments

Novartis Vaccines and Diagnostics, Inc. Wins $22.64 Million Federal Contract

Novartis Vaccines and Diagnostics, Inc. was awarded a firm-fixed-price federal contract modification valued at up to $22,644,000 by the Defense Logistics Agency Troop Support, Philadelphia, for vaccines to be used by the U.S. Army, U.S. Navy, U.S. Air U.S. Force and U.S. Marine Corps in Massachusetts and United Kingdom. The contract has one option year.

Microbix Biosystems Inc. Updates its VIRUSMAX Patent Infringement Lawsuit Against Novartis Vaccines and Diagnostics

Microbix Biosystems Inc. announced that the Court of Dusseldorf, Germany has dismissed its VIRUSMAX(r) patent infringement lawsuit against Novartis Vaccines and Diagnostics without prejudice. Microbix successfully obtained VIRUSMAX patents in 21 countries between 2006 and 2011 claiming methods for the improvement of virus yields in the manufacture of influenza and related vaccines. In 2010 Novartis filed an Opposition at the European Patent Office (EPO) in Munich against Microbix' European Patent 1 636 352 B1. The EPO rejected the Opposition at its Hearing in January 2014. The EPO has not yet addressed Novartis' appeal of its decision. In July 2014, Microbix filed a lawsuit against Novartis for infringement of its patent in Germany, based on evidence published on the internet by students disclosing material authored by Novartis employees in the US and the UK, which Microbix discovered in November 2013. Microbix endeavoured to obtain further evidence of infringement of the Italian portion of the EPO Patent by filing an additional action against Novartis in July 2014 in the Court of Rome, Italy. The Court of Rome subsequently granted Microbix a Seizure Order, which allowed Court officials to seize Novartis' regulatory, development and manufacturing records at their Italian manufacturing facilities, in July 2014. Meanwhile, Novartis filed an action in Italy seeking nullification of Microbix' Italian patent, an action to which Microbix is responding. Novartis filed multiple motions with the Court of Rome demanding additional confidentiality provisions, which delayed the review of documents by Microbix. The Court of Dusseldorf has dismissed the infringement action without prejudice on March 26. This decision is fully appealable. Microbix' counsel is completing the examination of Novartis' records and will determine whether to file its infringement complaint based on the outcome of its review.

Novartis Vaccines and Diagnostics Wins Federal Contract for VFA 2014

Centers for Disease Control and Prevention (Department of Health and Human Services), Procurement and Grants Office (Atlanta), has awarded a $14,642,400.00 (Estimated) federal contract to Novartis Vaccines And Diagnostics for "VFA 2014 on July 1, 2014.

Similar Private Companies By Industry

Company Name Region
By-Prod Corporation United States
Mylan LLC United States
Wellesley Pharmaceuticals LLC United States
Companion Pharma, Inc. United States
DPT Laboratories, Ltd. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novartis Vaccines and Diagnostics, Inc., please visit www.novartisvaccines.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.